Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATYR
Upturn stock ratingUpturn stock rating

aTyr Pharma, Inc. (ATYR)

Upturn stock ratingUpturn stock rating
$5.07
Last Close (24-hour delay)
Profit since last BUY31.01%
upturn advisory
Consider higher Upturn Star rating
BUY since 24 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ATYR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $19.35

1 Year Target Price $19.35

Analysts Price Target For last 52 week
$19.35Target price
Low$1.48
Current$5.07
high$5.98

Analysis of Past Performance

Type Stock
Historic Profit -17.09%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 447.69M USD
Price to earnings Ratio -
1Y Target Price 19.35
Price to earnings Ratio -
1Y Target Price 19.35
Volume (30-day avg) 11
Beta 0.87
52 Weeks Range 1.48 - 5.98
Updated Date 06/30/2025
52 Weeks Range 1.48 - 5.98
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.82%
Return on Equity (TTM) -79.7%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 384333313
Price to Sales(TTM) 1147.59
Enterprise Value 384333313
Price to Sales(TTM) 1147.59
Enterprise Value to Revenue 132.17
Enterprise Value to EBITDA -0.81
Shares Outstanding 89004400
Shares Floating 86984035
Shares Outstanding 89004400
Shares Floating 86984035
Percent Insiders 2.23
Percent Institutions 69.63

Analyst Ratings

Rating 4
Target Price 19.35
Buy 4
Strong Buy 7
Buy 4
Strong Buy 7
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

aTyr Pharma, Inc.

stock logo

Company Overview

overview logo History and Background

aTyr Pharma, Inc. was founded in 2003. It focuses on the discovery and development of medicines based on novel biological pathways.

business area logo Core Business Areas

  • Protein-based therapeutics: Develops protein-based therapeutics for severe immune-mediated diseases. Lead candidate is efzofitimod for pulmonary sarcoidosis.

leadership logo Leadership and Structure

John Mendlein, PhD, serves as Chairman of the Board. The company has a management team responsible for research, development, and operations. The organization is structured around research and clinical development functions.

Top Products and Market Share

overview logo Key Offerings

  • Efzofitimod: Efzofitimod is a selective modulator of Neuropilin-2 (NRP2) designed to downregulate innate and adaptive immune responses in inflammatory diseases. It is in clinical development for pulmonary sarcoidosis. Market share is currently 0 due to pre-commercialization stage. Competitors include companies targeting sarcoidosis with different mechanisms of action (e.g., anti-TNF agents).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is competitive, with significant investment in research and development. The market for immune-mediated diseases is substantial and growing.

Positioning

aTyr Pharma focuses on novel pathways with efzofitimod and related compounds. They are targeting unmet needs in severe immune-mediated diseases.

Total Addressable Market (TAM)

The total addressable market for sarcoidosis and other immune-mediated diseases is estimated to be in the billions of dollars. aTyr Pharma's positioning with efzofitimod allows them to target a specific segment of this market.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach targeting NRP2
  • Lead candidate in clinical development (efzofitimod)
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Reliance on a single lead candidate
  • Clinical trial risks and uncertainties

Opportunities

  • Positive clinical trial results for efzofitimod
  • Partnerships and collaborations with larger pharmaceutical companies
  • Expansion of pipeline into other immune-mediated diseases

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and approval delays
  • Failure of clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • Johnson & Johnson (JNJ)
  • AbbVie (ABBV)
  • Bristol Myers Squibb (BMY)

Competitive Landscape

aTyr Pharma is a smaller company competing with larger pharmaceutical companies in the immune-mediated disease space. Its competitive advantage lies in its novel therapeutic approach targeting NRP2. Disadvantages include limited resources and reliance on a single lead candidate.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by preclinical and clinical development progress.

Future Projections: Future projections depend on the success of efzofitimod in clinical trials and potential regulatory approval. Analyst estimates vary.

Recent Initiatives: Recent initiatives include advancing efzofitimod through clinical trials and exploring potential partnerships.

Summary

aTyr Pharma is a development-stage biopharmaceutical company with a novel therapeutic approach. The success of efzofitimod is critical to its future. The company faces significant clinical trial and regulatory risks and needs to manage its limited resources effectively. Positive clinical data and potential partnerships are key to its growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • aTyr Pharma's website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Data is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About aTyr Pharma, Inc.

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2015-05-07
President, CEO & Director Dr. Sanjay S. Shukla M.D., M.S.
Sector Healthcare
Industry Biotechnology
Full time employees 56
Full time employees 56

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.